Xofluza from Roche’s Genentech unit was approved by the FDA for patients over the age of 12, and the company is hoping the label will be expanded to include children. But a new study out of the University of Wisconsin
read moreThe Institute for Clinical and Economic Review (ICER) released the latest iteration of its draft assessment of the cost effectiveness of JAK inhibitors to treat rheumatoid arthritis (RA). AbbVie’s Rinvoq comes off a bit better than it did in an
read moreMore: Manufacturing News of Note: Aurobindo gets two 483s; Catalent to make BeiGene drug Source: fierce
read moreAcadia’s Nuplazid suffered a big loss in July after a late-stage trial as an add-on treatment for schizophrenia fell flat. But that study wasn’t Nuplazid’s last go at the indication, and now a win from the phase 2 Advance study
read moreDespite the majority of healthcare professionals thinking that general analysis of data would help enable quicker diagnosis, most don’t trust “big tech” companies to do it. More: NHS has ‘big tech’ patient data analysis fears Source: News
read moreThe treatment reduced haemoglobin A1c by 0.19% and LDL-C by 25% in those not on statin background therapy. More: Pooled bempedoic acid data shows success in cholesterol, haemoglobin Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals